Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 2Terminated 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 26Genitourinary 16Other hematologic neoplasm 14Lymphoid 10Gastrointestinal 7Breast 7Gynecologic 6Thoracic 5Head & Neck 3CNS 3Other solid neoplasm 2Myeloid 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interleukin-2 × Plasma cell × Clear all
NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡